Table 1 Clinical baseline information of GC patients

n

187

188

T stage, n (%)

T1

13 (3.5%)

6 (1.6%)

T2

40 (10.9%)

40 (10.9%)

T3

91 (24.8%)

77 (21%)

T4

40 (10.9%)

60 (16.3%)

N stage, n (%)

N0

56 (15.7%)

55 (15.4%)

N1

53 (14.8%)

44 (12.3%)

N2

37 (10.4%)

38 (10.6%)

N3

34 (9.5%)

40 (11.2%)

M stage, n (%)

M0

169 (47.6%)

161 (45.4%)

M1

8 (2.3%)

17 (4.8%)

Pathologic stage, n (%)

Stage I

28 (8%)

25 (7.1%)

Stage II

62 (17.6%)

49 (13.9%)

Stage III

73 (20.7%)

77 (21.9%)

Stage IV

14 (4%)

24 (6.8%)

Primary therapy outcome, n (%)

PD

36 (11.4%)

29 (9.1%)

SD

8 (2.5%)

9 (2.8%)

PR

0 (0%)

4 (1.3%)

CR

114 (36%)

117 (36.9%)

Gender, n (%)

Female

62 (16.5%)

72 (19.2%)

Male

125 (33.3%)

116 (30.9%)

Race, n (%)

Asian

38 (11.8%)

36 (11.1%)

Black or African American

7 (2.2%)

4 (1.2%)

White

119 (36.8%)

119 (36.8%)

Age, n (%)

 ≤ 65

88 (23.7%)

76 (20.5%)

 > 65

99 (26.7%)

108 (29.1%)

Histological type, n (%)

Diffuse type

24 (6.4%)

39 (10.4%)

Mucinous type

6 (1.6%)

13 (3.5%)

Not otherwise specified

114 (30.5%)

93 (24.9%)

Papillary type

2 (0.5%)

3 (0.8%)

Signet ring type

1 (0.3%)

10 (2.7%)

Tubular type

40 (10.7%)

29 (7.8%)

Residual tumor, n (%)

R0

153 (46.5%)

145 (44.1%)

R1

5 (1.5%)

10 (3%)

R2

7 (2.1%)

9 (2.7%)

Histologic grade, n (%)

G1级

5 (1.4%)

5 (1.4%)

G2级

79 (21.6%)

58 (15.8%)

G3级

101 (27.6%)

118 (32.2%)

H pylori infection, n (%)

No

71 (43.6%)

74 (45.4%)

Yes

8 (4.9%)

10 (6.1%)

History of reflux, n (%)

No

96 (44.9%)

79 (36.9%)

Yes

13 (6.1%)

26 (12.1%)

Antireflux treatment, n (%)

No

74 (41.3%)

68 (38%)

Yes

12 (6.7%)

25 (14%)

Anatomic neoplasm subdivision, n (%)

Antrum/distal

67 (18.6%)

71 (19.7%)

Cardia/proximal

27 (7.5%)

21 (5.8%)

Fundus/body

64 (17.7%)

66 (18.3%)

Gastroesophageal junction

19 (5.3%)

22 (6.1%)

Other

3 (0.8%)

1 (0.3%)

Barretts esophagus, n (%)

No

95 (45.7%)

98 (47.1%)

Yes

10 (4.8%)

5 (2.4%)

Age, meidan (IQR)

65.06 ± 10.93

66.61 ± 10.33